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Functionalization of Ruthenium(II) terpyridine complexes with 
cyclic RGD peptides to target integrin receptors in cancer cells 
Eva M. Hahn,[a,b] Natalia Estrada-Ortiz,[c] Jiaying Han,[c] Vera F. C. Ferreira,[d] Tobias G. Kapp,[e] João 
D. G. Correia,[d] Angela Casini[b,c,e*] and Fritz E. Kühn[a,*] 
Abstract: The lack of selectivity for cancer cells and the resulting negative impact on healthy tissue is a severe drawback of actual cancer 
chemotherapy. Tethering of cytotoxic drugs to targeting vectors such as peptides, which recognize receptors overexpressed on the surface of 
tumor cells, is one possible strategy to overcome such a problem. The pentapeptide cyc(RGDfK) targets the integrin receptor αvβ3, important 
for tumor growth and metastasis formation. In this work, two terpyridine based Ru(II) complexes were prepared and for the first time conjugated 
to cyc(RGDfK) via amide bond formation resulting in a monomeric and a dimeric bioconjugate. Both Ru(II) complexes bind strongly and 
selectively to integrin αvβ3, with the dimeric molecule displaying a 20-fold higher affinity to the receptor than the monomeric one. However, the 
cytotoxicity of the complexes and related bioconjugates against human A549 and SKOV-3 cell lines is still not sufficient for application as 
anticancer agents. Nevertheless, considering the high selectivity for integrin receptor αvβ3, the synthesis of Ru-based bioconjugates with 
cyc(RGDfK) paves a promising way towards the design of effective targeted anticancer agents.  
Introduction 
Platinum anticancer drugs are widely used for chemotherapy of various cancers. However, indiscriminate distribution or poor selectivity 
often results in severe side effects and drug resistance.[1] Therefore, enhancing the tumor selectivity has become a major goal for the 
development of platinum-based cytotoxic agents. Similar issues are encountered with the new generation of experimental anticancer 
metal complexes, including, among others, compounds based on 
ruthenium,[2] gold,[3] iron[4] and copper[5]. Thus, the development of 
so-called targeting and drug delivery strategies of metallodrugs 
has become a priority in the field, together with the design of new 
chemical scaffolds. 
Within this framework, an increasing number of reports on 
tethering metal complexes to a wide range of functional molecules 
or nanoparticles with or without targeting groups has appeared in 
recent years.[6] Specifically, the functionalization of metallodrugs 
is aimed at improving the tumor selectivity and/or minimizing the 
systemic toxicity to enhance their cellular accumulation and 
overcome tumor resistance. Moreover, a synergistic anticancer 
effect of different therapeutic modalities would also be welcome. 
In some cases, the use of imaging tags conjugated to the metal 
compounds allow to visualize the drug molecules in vitro or in vivo, 
thus leading to the design of theranostic agents.[7]  
Among the various strategies explored so far to actively target cytotoxic metallodrugs to cancer cells, tumor-targeting peptides (TTPs) 
that are specific for tumor related surface markers, such as membrane receptors, can be used.[8]  
Integrin receptors have been largely explored as drug targets since they are heterodimeric, transmembrane receptors that function as 
mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. [9] Integrins interact with 
the extracellular matrix (ECM) thereby regulating many cellular functions, such as proliferation, migration, and survival. Integrins are 
also involved in the cell-to-cell interactions. Through cell–cell and cell–ECM contacts, the integrins transduce the information from the 
external environment into the cell and vice-versa, to promote cell adhesion, spreading and motility.[10] One common feature of the 
integrin family is a heterodimeric structure that consists of 
 
and  subunits.[11] These structures form 24 different subtypes in mammals, 
which can be classified according to their binding partners (e.g. laminin, collagen). Different integrins are also associated with tumor 
angiogenesis and metastasis,[12] being upregulated in tumor cells compared to low levels in normal endothelial cells. The integrin 
receptor v3 plays a crucial role in these processes[13],[14] and  became an attractive target for pharmaceutical research.[15]  
In 1984, Pierschbacher and Ruoslahti discovered that the amino acid sequence Arg-Gly-Asp-Ser (RGDS) is essential for binding 
integrin receptors.[16] In fact, eight of the above mentioned integrin subtypes form the RGD-binding class.[17] Since then, a wide 
screening of peptide libraries has been carried out to discover ligands including the RGD sequence, and targeting the integrin receptors 
with even higher selectivity. Interestingly, the cyclic pentapeptide cyc[RGDfK] (Figure 1) was found to have increased selectivity for 
integrin v3.[18] 
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Figure 1. Cyclic pentapeptide cyc[RGDfK] (A) and two representative targeted Pt constructs: a Pt(IV) conjugate[19] (B) and nanoparticles encapsulating a cisplatin 
prodrug[20] (C).  
Among the metal-based radiopharmaceuticals tethered to cyclic RGD peptides, the majority of the examples reported in the literature 
have been evaluated as SPECT and PET radiotracers for tumor imaging. [7a, 21] Recently, the preclinical evaluation of the potential 
theranostic radiopharmaceutical 66Ga-DOTA-E(cyc[RGDfK])2 compound has been reported.[22] 
As an example of targeted anticancer metal complexes, recent reports describe the synthesis and biological evaluation of Pt(IV) 
prodrugs, whose axial positions could be functionalized with cyclic RGD tripeptides that bind selectively to the integrin receptor v3.[[19, 
23]
 In a more elaborated approach, Lippard et al. synthesized a cisplatin prodrug encapsulated into poly(D,L-lactic-co-glycolic acid)-
block-polyethylene glycol (PLGA-PEG) nanoparticles tethered to cyc[RGDfK]. The prodrug shows a significant increase in cytotoxicity 
towards v3 integrin–expressing cancer cell lines, comparable to cisplatin. In vivo studies also revealed equivalent tumor growth 
inhibition (ca. 60%) by both the prodrug and cisplatin in mice bearing ovarian cancer xenografts. [20] 
Concerning anticancer ruthenium complexes coupled to peptides, some examples have been already reported in the literature,[8] 
including luminescent Ru(II) complexes linked through the mitochondrial penetrating peptide (MPP),[24] as well as to the nuclear 
localization sequence (NLS),[25] the latter enabling the active transport of drugs into the cell nucleus as confirmed by fluorescence 
microscopy studies. Interestingly, Keyes et al. developed ruthenium(II) polypyridyl luminophores anchored to peptide sequences as a 
new class of stimulated emission depletion (STED) microscopy probes for imaging of key cell organelles.[26] Ueyama et al. also 
described a peptide labeling approach using Ru(II) terpyridine complexes, to implement the mass spectrometry detection of proteolytic 
peptides.[27] 
As far as it concerns RGD-type peptides, only a few examples are described. Thus, Sadler et al. reported the synthesis of a Ru(II) 
arene complex attached to the linear RGD tripeptide[28], which dissociates from the peptide by irradiation with visible light to form an 
aqua complex that generates monofunctional adducts with guanine bases of the DNA. Furthermore, Adamson et al. designed 
luminescent Ru(II) polypyridyl complexes attached to the linear RGD tripeptide, acting as molecular probes for reporting on the 
presence and conformation of integrins.[29] Live cell studies with confocal microscopy confirmed the selective binding to an integrin 
receptor, but no cytotoxicity studies were described. 
Finally, fluorescent ruthenium polypyridyl complexes have been attached to RGD-functionalized mesoporous silica nanoparticles,[30] 
whose uptake and sub-cellular distribution could be followed by fluorescence microscopy. Interestingly, the RDG peptide on the 
nanoparticle surface induces an increased selectivity for cancer cells. After internalization of the nanoparticle, the ruthenium species 
are released and induce changes in the phosphorylation pathway of certain protein kinases leading to apoptosis.  
To the best of our knowledge, besides the above mentioned publications, there are no further studies about conjugation of ruthenium 
complexes to RGD-type peptides. Therefore, in this work the successful bioconjugation of two Ru(II) terpyridine complexes to the cyclic 
RGD peptide cyc[RGDfK] for targeting integrin v3 is reported. The two Ru(II) compounds were designed to feature carboxylic acid 
groups for conjugation to the lysine residue of the RGD peptide via amide bond formation. Thus, the compounds were tethered to one 
or two peptides. In the latter case, anchoring to two cyc[RGDfK] were intended to enhance the binding affinity to the v3 integrin 
receptor.[13] The binding affinities of the ruthenium-RGD conjugates for both the v3 and 51 integrin receptors have been evaluated 
by integrin binding assays. The anticancer effects of the “free” ruthenium complexes and their respective conjugates were evaluated in 
vitro against human cancer cell lines with different expression levels of integrin v3, namely human lung cancer A549 cells (scarce v3 integrin expression) and human mammary carcinoma SKOV3 cells (moderate v3 integrin expression).[31] 
Results and Discussion 
The experimental procedures can be found in the Supporting Information. The two ligands used in this work are 2,2':6',2''-terpyridine 
(terpy, 1a) and [2,2':6',2''-terpyridine]-4'-carboxylic acid (terpy*, 1b). For the synthesis of 1b a reported two step procedure has been 
followed.[32] In the first step, 2-acetylpyridine and furfural were combined in ethanol under basic conditions to yield 4'-(furan-2-yl)-
  
 
 
 
terpyridine, which was oxidized in the following step with KMnO4 to obtain [2,2':6',2''-terpyridine]-4'-carboxylic acid (terpy*, 1b) (see 
Scheme 1).  
Scheme 1. Synthesis of ligand 1b, [2,2':6',2''-terpyridine]-4'-carboxylic acid. 
The complexes 3a and 3b were prepared by a novel synthetic route based on literature procedures[33] (Scheme 2). Heating RuCl33H2O 
with 1a or 1b in dry ethanol yields the brown complexes 2a and 2b, respectively, after one hour in the dark. Afterwards, the complexes 
reacted with 1b, triethylamine and LiCl for chloride abstraction and reduction of Ru(III) to Ru(II). Upon addition of 1 M KPF6 solution, 
the complexes [Ru(terpy)(terpy*)](PF6)2 (3a) and [Ru(terpy*)2](PF6)2 (3b) bearing one or two carboxylic acid groups, respectively, 
precipitate. 
 
 
 
 
 
 
 
Scheme 2. Two step procedure for the synthesis of [Ru(terpy)(terpy*)](PF6)2 (3a) and [Ru(terpy*)2](PF6)2 (3b). 
The conjugation of 3a and 3b to the cyclic peptide cyc[R(Pbf)GD(tBu)fK] was accomplished by reaction of the free carboxylic acid 
groups of the complexes with the primary amine of the lysine side chain in the presence of a mixture of the activating agents HATU 
and HOAt (Scheme 3). The success of the bioconjugation reaction was confirmed by Electrospray Ionisation Mass Spectrometry (ESI-
MS), which allowed to identify the intermediate products at m/z = 752.78 for [Ru(terpy)(terpy-cyc(R(Pbf)GD(tBu)fK))]2+ and 1221.58 for 
[Ru(terpy-cyc(R(Pbf)GD(tBu)fK))2]2+, respectively. Afterwards, the remaining protection groups of Arg and Asp were cleaved using a 
cleavage cocktail as detailed in the experimental section. For purification of the crude product, size exclusion chromatography with 
Sephadex® G-15 was used since the compounds decomposed during reverse phase (RP)-HPLC. Finally, the products were precipitated 
by addition of solid KPF6 to give [Ru(terpy)(terpy-cyc(RGDfK)](PF6)2 (4a) and [Ru(terpy-cyc(RGDfK))2](PF6)2 (4b) as red solids.  
 
 
 
 
 
 
 
 
Scheme 3. Synthesis of the bioconjugate products 4a and 4b (PG = protecting group). 
 
 
 
 
 
 
  
 
 
 
Characterization of the ligand 1b complexes 3a,b and 4a,b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 1H NMR spectra of 1b and complexes 3a and 3b (in DMSO-d6). 
The ligands and the corresponding complexes were characterized by 1H-, 13C- and 31P-NMR spectroscopy and ESI-MS.  
Comparing the 1H NMR spectra of ligand 1b with 3a, several signal shifts are observed due to complex formation (Figure 2). The signals 
of H3’,5’ and H3,3’’ are shifted downfield around ∆δ = +0.61 or +0.49 ppm. In contrast, the signal of H4,4’’ remains and the signals of H6,6’’ 
and H5,5’’ show a strong upfield shift of ∆δ = −1.25 and −0.28 ppm. Nearly the same values are observed for complex 3b containing two 
ligands 1b. The downfield shift of H3’,5’ and H3,3’’ is about ∆δ = +0.62 and +0.47 ppm, whereas the signal of H4,4’’ remains and the signals 
of H6,6’’ and H5,5’’ are shifted upfield about ∆δ = −1.20 and −0.26 ppm. For these observations, two effects have to be taken into account: 
first, the deshielding effect of the carboxylic acid group and second, the increase of electron density in the aromatic system through 
coordination of ruthenium. The remaining signals in the spectrum of 3a can be assigned to coordinated ligand 1a. In the 31P NMR 
spectra the presence of the PF6- counter ions in complexes 3a and 3b is confirmed by the characteristic septet.  
The complexes 3a and 3b and their conjugation derivatives 4a and 4b were characterized by ESI-MS, where the characteristic isotopic 
patterns are consistent with the assigned structures (Figure S3-S14 in the supplementary material). The ESI-MS spectra of the 
complexes show signals at 757.05 and 306.04 m/z for 3a and 801.04 and 328.04 m/z for 3b, which indicate the loss of one or two PF6- 
anions, leading to a single or double positive charge cationic species. Similarly, for the coupling products 4a and 4b, the loss of PF6- 
anions is observed. The characteristic isotopic patterns of the signals match perfectly with the calculated ones, which can be seen in 
the supporting information.  
 
Integrin binding assay 
 
The impact of the conjugation of Ru(II) complexes to cyc[RGDfK] on the binding affinity to the integrin receptors αvβ3 and α5β1 was 
evaluated. The binding affinities for 4a, 4b and benchmark Cilengitide[34] are shown in Table 1.  
 4a exhibits an IC50 value of 49 ± 4.3 nM, 90 fold higher than Cilengitide (0.54 ±0.06 nM). However, the selectivity for αvβ3 is reasonably 
high reflecting the fact that the bioconjugate does not bind the α5β1 receptor at all (IC50  1000 nM), while Cilengitide has still an affinity 
of 15.4 ± 0.2 nM. Considering bioconjugate 4b, enhanced binding affinities are predicted due to its dimeric character. Indeed, the 
binding affinity for integrin αvβ3 is 2.5 ± 0.3 nM, presenting a 20 times higher affinity than that observed for the monomeric product and 
nearly approaching the value of Cilengitide. Since the affinity for the α5β1 receptor shows merely a value about 595 ± 67 nM, the high 
selectivity of 4b for αvβ3 is demonstrated.  
 
Table 1. Results of integrin binding assays for the bioconjugates 4a and 4b, in comparison to the benchmark Cilengitide.[a] 
 
IC50 [nM] ± SD 
Compound 3 51 
Cilengitide[34] 0.54 ± 0.06 15.4 ± 0.2 
4a 49 ± 4.3 >1000 
4b 2.5 ± 0.3 595 ± 67 
 
[a] The reported IC50 values were determined using a solid-phase binding assay (see the Supporting Information for details).  
 
 
  
 
 
 
Antiproliferative activity  
 
The ruthenium compounds (3a and 3b) and their respective cyc[RGDfK] bioconjugates (4a and 4b) were evaluated for their 
antiproliferative properties on two human cancer cell lines with scarce (A549) or moderate (SKOV3) expression of integrins αvβ3.[31] 
Unfortunately, both the ruthenium(II) complexes and their targeted derivatives show similarly very low cytotoxic effects against both cell 
lines, independent of the presence of the RGD domains (Table 2). This could be attributed to the intrinsic limited anticancer effects of 
the selected Ru(II) derivatives. Therefore, although their cell uptake should be favored by the presence of cyc[RGDfK] domains, in the 
end no toxic effects are observed. 
 
Table 2. IC50 values of Ru complexes and their RGD bioconjugates against human A549 and SKOV-3 cell lines. 
IC50 [µM][a] 
Compound A549 SKOV-3 
3a 70.3 ± 9.8 74.5 ± 13.7 
4a 87.7 ± 5.4 85.2 ± 18.7 
3b >100 >100 
4b >100 >100 
[a] The reported values are the mean ± SD of at least three determinations. 
Conclusions 
In summary, two novel ruthenium(II) polypyridyl complexes coupled to the cyclic pentapeptide cyc[RGDfK] with monomeric or dimeric 
character have been prepared in order to deliver anticancer metallodrugs directly to tumors cells overexpressing the αvβ3 integrin 
receptor.  
The preparation of the terpy-based ruthenium complexes 3a and 3b bearing one or two carboxylic acid groups, respectively, was 
carried out using a novel synthetic strategy. The compounds were coupled to a protected derivative of the cyclic pentapeptide via amide 
bond formation between the carboxylic acid of the complex and the amine group of the lysine side chain. Purification of the resulting 
monomeric (4a) or dimeric (4b) bioconjugates and was achieved by Size Exclusion Chromatography followed by precipitation as PF6-
salt. Considering the binding affinities of the bioconjugates towards the integrin receptors, a high selectivity for the αvβ3 integrin receptor 
and a negligible impact on the α5β1 receptor was observed. Still, the cytotoxicity of all the reported bioconjugates was low, most likely 
due to still scarce uptake in cancer cells. Hence, while the reported strategy holds promise to achieve targeted metallodrugs, future 
studies have to focus on the tethering to the RGD peptide of ruthenium complexes with an intrinsically higher cytotoxic potency, such 
as similar types of ruthenium complexes with terpyridine-type ligands [35]. 
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